{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:13:11Z","timestamp":1791133991577,"version":"4.1.0"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Y143C,R substitutions in HIV-1 integrase define one of three primary raltegravir (RAL) resistance pathways. Here we describe clinical isolates with alternative substitutions at position 143 (Y143A, Y143G, Y143H, and Y143S [Y143A,G,H,S]) that emerge less frequently, and we compare the genotypic and phenotypic profiles of these viruses to Y143C,R viruses to reconcile the preferential selection of Y143C,R variants during RAL treatment. Integrase amino acid sequences and RAL susceptibility were characterized in 117 patient isolates submitted for drug resistance testing and contained Y143 amino acid changes. The influence of specific Y143 substitutions on RAL susceptibility and their preferential association with particular secondary substitutions were further defined by evaluating the composition of patient virus populations along with a large panel of site-directed mutants. Our observations demonstrate that the RAL resistance profiles of Y143A,G,H,S viruses and their association with specific secondary substitutions are similar to the well-established Y143C profile but distinct from the Y143R profile. Y143R viruses differ from Y143A,C,G,H,S viruses in that Y143R confers a greater reduction in RAL susceptibility as a single substitution, consistent with a lower resistance barrier. Among Y143A,C,G,H,S viruses, the higher prevalence of Y143C viruses is the result of a lower genetic barrier than that of the Y143A,G,S viruses and a lower resistance barrier than that of the Y143H viruses. In addition, Y143A,C,G,H,S viruses require multiple secondary substitutions to develop large reductions in RAL susceptibility. Patient-derived viruses containing Y143 substitutions exhibit cross-resistance to elvitegravir.<\/jats:p>","DOI":"10.1128\/aac.00204-13","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T00:46:00Z","timestamp":1370306760000},"page":"4105-4113","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":27,"title":["Multiple Genetic Pathways Involving Amino Acid Position 143 of HIV-1 Integrase Are Preferentially Associated with Specific Secondary Amino Acid Substitutions and Confer Resistance to Raltegravir and Cross-Resistance to Elvitegravir"],"prefix":"10.1128","volume":"57","author":[{"given":"Wei","family":"Huang","sequence":"first","affiliation":[{"name":"Monogram Biosciences, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Frantzell","sequence":"additional","affiliation":[{"name":"Monogram Biosciences, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Fransen","sequence":"additional","affiliation":[{"name":"Monogram Biosciences, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos J.","family":"Petropoulos","sequence":"additional","affiliation":[{"name":"Monogram Biosciences, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.11.5728-5736.2004"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(02)00952-1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.4.1339"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2171144"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5453.646"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2012.09.033"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60597-2"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708978"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708975"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/597290"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181da1287"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"379","author":"DeJesus E","year":"2012","unstructured":"DeJesusERockstrohJKHenryKMolinaJMGatheJRamanathanSWeiXYaleKSzwarcbergJWhiteKChengAKKearneyBP. 2012. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 379:2429\u20132438.","journal-title":"Lancet"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60917-9"},{"key":"e_1_3_2_15_2","volume-title":"Dolutegravir (DTG; S\/GSK1349572)+abacavir\/lamivudine once daily statistically superior to tenofovir\/emtricitabine\/efavirenz: 48-week results-SINGLE (ING114467)","author":"Walmsley S","year":"2012","unstructured":"WalmsleySAntelaAClumeckNDuiculescuDEberhardAGutierrezFHocquelouxLMaggioloFSandkovskyUGranierCWynneBPappaK. 2012. Dolutegravir (DTG; S\/GSK1349572)+abacavir\/lamivudine once daily statistically superior to tenofovir\/emtricitabine\/efavirenz: 48-week results-SINGLE (ING114467). 52th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annu. Meet., San Francisco, CA."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01228-07"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01168-09"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010311"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01075-09"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp477"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00470-08"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06170-11"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02568-12"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283473599"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp014"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq099"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834b34de"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06618-11"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir025"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn1050"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00071-11"},{"key":"e_1_3_2_32_2","volume-title":"Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of raltegravir (MK-0518), a novel HIV- integrase inhibitor, in patients with triple-class resistant virus, abstr. 105a LB","author":"Cooper D","year":"2007","unstructured":"CooperDGatellJMRockstrohJKatlamaCYeniPLazzarinAChenJIsaacsRTepplerHNguyenB, Group Benchmark Study Team. 2007. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of raltegravir (MK-0518), a novel HIV- integrase inhibitor, in patients with triple-class resistant virus, abstr. 105a LB. 14th Conf. Retrovir. Opportun. Infect., Los Angeles, CA."},{"key":"e_1_3_2_33_2","first-page":"404","article-title":"The \u201cmegaprimer\u201d method of site-directed mutagenesis","volume":"8","author":"Sarkar G","year":"1990","unstructured":"SarkarGSommerSS. 1990. The \u201cmegaprimer\u201d method of site-directed mutagenesis. Biotechniques 8:404\u2013407.","journal-title":"Biotechniques"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040514"},{"key":"e_1_3_2_35_2","unstructured":"WhiteKLKulkarniRSzwarcbergJQuirkEChengAKMillerMD. 2012. Integrated analysis of emergent drug resistance from the HIV-1 phase 3 QUAD studies through week 48. Antivir. Ther. 17:A12."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2012.08.004"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08784"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00204-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00204-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:29:23Z","timestamp":1645482563000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00204-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1128\/AAC.00204-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.00204-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"2013-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-05-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}